Portfolio News

Four technologies that could change the face of medicine

The field of electronic eyeglasses is another exciting example of how advanced technology can help manage conditions that once had few treatment options.
The eSight system, for example, is allowing many who are legally blind to see, using a device that resembles a virtual reality headset. The system captures high-definition video and then optimizes the images into a viewable format, adjusting the image depending on the user’s eye condition. Read more >>

Seeing a brighter future with eSight

Miracle Villanueva, who is 6 years old and blind, saw her mother for the first time on Thursday.
“I’m so excited and happy,” said Suzanna Emanuel, the mother of the aptly named Miracle. “She will have a better future to look forward to. In school she has a tough time, but these glasses will let her get an education.” Read more >>

Platelet BioGenesis Moves to New Cambridge Lab Space to Support Continued Growth

Platelet BioGenesis (PBG), the leader in the production of functional human platelets (PLTs+™) from stem cells and the development of platelet-based therapeutics, announced it has moved into brand new lab space in Cambridge, MA. Located next to MIT, the newly renovated property puts Platelet BioGenesis in the heart of the most dynamic biotech cluster in the world. Read more >>

Mohamad Ali, CEO & President, Carbonite Delivers Keynote Address at WOW!NOW Breakfast

At our annual WOW!NOW celebration in Boston, Mohamad Ali spoke about the importance of hiring employees with diverse perspectives and skillsets, how Citizen Schools is helping to close the ‘IT skills gap,’ and called on our cities, states and country to come together to provide opportunities for all students to have an equal opportunity for high-quality education. Read more >>

Siamab Therapeutics Announces Publication in PLOS ONE of Positive Data from Preclinical Studies of its ST1 Antibody Therapeutic in Development for Ovarian Cancer

Siamab Therapeutics, Inc., a biopharmaceutical company developing novel glycan-targeted cancer therapeutics, today announced the publication of positive preclinical data for its ST1 antibody drug conjugate (ADC) in multiple models of ovarian cancer. Siamab’s lead ST1 program targets Sialyl-Tn (STn), a tumor-associated carbohydrate antigen (TACA), which is expressed on ovarian and other solid tumors and is associated with metastatic disease, poor prognosis, chemo-resistance, and reduced overall survival. Read more >>

Corbus Pharmaceuticals to Commence Phase 3 Study of Lenabasum for the Treatment of Rare Autoimmune Disease Dermatomyositis

Corbus Pharmaceuticals Holdings, Inc., a clinical stage drug development company targeting rare, chronic, serious inflammatory and fibrotic diseases, announced today that the Company will proceed with a Phase 3 trial evaluating the efficacy and safety of lenabasum for the treatment of dermatomyositis (“DM”). Dermatomyositis is a rare and serious multisystem inflammatory autoimmune disease affecting muscle and skin. The U.S. Food and Drug Administration (“FDA”) provided guidance on the overall study design of this trial at a recent end-of-Phase 2 […]